.png){kind=icon}
.png){kind=icon}
Return
Inhibition of fibril formation by polyphenols: molecular mechanisms, challenges, and prospective solutions
.png){kind=icon}
PRE
AI
S
S
DOI：10.1039/d4cc00822g.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Fibril formation is a key feature in neurodegenerative diseases like Alzheimer's, Parkinson's, and systemic amyloidosis. Polyphenols, found in plant-based foods, show promise in inhibiting fibril formation and disrupting disease progression. The ability of polyphenols to break the amyloid fibrils of many disease-linked proteins has been tested in numerous studies. Polyphenols have their distinctive mechanism of action. They behave differently on various events in the aggregation pathway. Their action also differs for different proteins. Some polyphenols only inhibit the formation of fibrils whereas others break the preformed fibrils. Some break the fibrils into smaller species, and some change them to other morphologies. This article delves into the intricate molecular mechanisms underlying the inhibitory effects of polyphenols on fibrillogenesis, shedding light on their interactions with amyloidogenic proteins and the disruption of fibril assembly pathways. However, addressing the challenges associated with solubility, stability, and bioavailability of polyphenols is crucial. The current strategies involve nanotechnology to improve the solubility and bioavailability, thus showing the potential to enhance the efficacy of polyphenols as therapeutics. Advancements in structural biology, computational modeling, and biophysics have provided insights into polyphenol-fibril interactions, offering hope for novel therapies for neurodegenerative diseases and amyloidosis. Modulation of the aggregation pathway by polyphenols through interactions with various species generated during aggregation.
Keywords:
GAMMA-D-CRYSTALLIN
BLOOD-BRAIN-BARRIER
A-BETA COMPONENT
ALPHA-SYNUCLEIN
SUPEROXIDE-DISMUTASE
PARKINSONS-DISEASE
DRUG-DELIVERY
SECONDARY STRUCTURE
AMYLOID FIBRILS
AGGREGATION
Journal
IF:
4.2
Papers:
5.9W
Citations:
16.5W
Organization
Cited Papers